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Table S1 – Numbers of peptides in the PredivacDB database of high-affinity 
nonameric HLA class II ligands, indicating allele restriction and the respective 





IEDB MHCBN EPIMHC Full list Filtered list Binding core 
DRB1*0101 919 120 52 1091 1007 815 
DRB1*0102 23 0 5 28 25 25 
DRB1*0301 170 19 21 210 202 180 
DRB1*0401 355 201 126 682 541 450 
DRB1*0402 37 21 43 101 82 59 
DRB1*0403 8 0 2 10 10 7 
DRB1*0404 94 18 52 164 143 102 
DRB1*0405 62 18 35 115 102 75 
DRB1*0406 0 3 2 5 8 8 
DRB1*0407 0 0 5 5 9 9 
DRB1*0701 189 11 34 234 219 192 
DRB1*0801 4 0 36 40 40 33 
DRB1*0802 39 3 2 44 40 35 
DRB1*0901 10 4 3 17 13 11 
DRB1*1101 167 64 25 256 238 226 
DRB1*1102 0 0 1 1 1 1 
DRB1*1103 1 0 0 1 1 1 
DRB1*1104 9 0 8 17 17 17 
DRB1*1201 3 0 9 12 12 9 
DRB1*1301 9 0 19 28 26 17 
DRB1*1302 81 4 18 103 91 73 
DRB1*1401 2 0 4 6 6 4 
DRB1*1501 227 33 19 279 225 172 
DRB1*1502 0 0 7 7 7 7 
DRB1*1601 1 0 0 1 1 1 
DRB3*0101 10 1 2 13 8 7 
DRB3*0301 1 0 0 1 1 1 
DRB4*0101 50 1 3 54 52 49 
DRB5*0101 143 13 9 165 140 109 





Table S2 - Web-accessible methods for HLA class II binding prediction and CD4+ T 
cell epitope prediction employed in the benchmarking analysis 
 










TEPITOPEpan Virtual pockets Pan-specific http://www.biokdd.fudan.edu.cn/S
ervice/TEPITOPEpan/TEPITOPEp
an.html 
MultiRTA Thermodynamic principles Pan-specific http://www.bordnerlab.org/Multi
RTA/ 
IEDB (SMM-Align) Matrix Allele-specific http://www.immuneepitope.org/ 
IEDB (TEPITOPE) Matrix Allele-specific 
IEDB (ARB) Matrix Allele-specific 
SYFPEITHI Motifs Allele-specific http://www.syfpeithi.de/ 
Rankpep Matrix Allele-specific http://imed.med.ucm.es/Tools/ran
kpep.html 










Table S3 - Predictive performance (AUC values) for CD4+ T cell epitope prediction of 
four pan-specific methods 
 
Allele Epitopes PREDIVAC NetMHCIIPan TEPITOPE MultiRTA 
DRB1*0101 125 0.828 0.800 0.805 0.776 
DRB1*0102 4 0.860 0.869 0.846 0.828 
DRB1*0103 5 0.668 0.749 0.8 0.639 
DRB1*0301 173 0.658 0.693 0.643 0.657 
DRB1*0401 342 0.757 0.722 0.724 0.688 
DRB1*0402 33 0.574 0.589 0.616 0.551 
DRB1*0403 14 0.833 0.821 0.859 0.852 
DRB1*0404 46 0.762 0.718 0.747 0.712 
DRB1*0405 21 0.736 0.713 0.778 0.643 
DRB1*0406 6 0.775 0.684 0.815 0.845 
DRB1*0407 4 0.675 0.627 0.776 0.718 
DRB1*0408 2 0.963 0.997 0.956 0.987 
DRB1*0701 56 0.772 0.744 0.759 0.749 
DRB1*0703 1 1.000 0.864 0.914 0.717 
DRB1*0801 4 0.714 0.684 0.624 0.657 
DRB1*0802 2 0.929 0.695 0.85 0.735 
DRB1*0803 2 0.645 0.875 0.587 0.706 
DRB1*0901 13 0.701 0.669 0.745 0.642 
DRB1*1001 4 0.700 0.796 0.805 0.712 
DRB1*1101 88 0.710 0.78 0.733 0.688 
DRB1*1102 1 0.387 0.452 0.854 0.441 
DRB1*1103 3 0.337 0.518 0.317 0.492 
DRB1*1104 6 0.855 0.772 0.832 0.688 
DRB1*1201 3 0.911 0.961 0.887 0.87 
DRB1*1301 15 0.815 0.563 0.717 0.613 
DRB1*1302 10 0.721 0.772 0.749 0.764 
DRB1*1303 3 0.449 0.621 0.576 0.512 
DRB1*1401 16 0.561 0.734 0.719 0.687 
DRB1*1404 1 0.640 0.941 0.954 0.942 
DRB1*1405 2 0.670 0.896 0.819 0.923 
DRB1*1501 193 0.686 0.667 0.654 0.638 
DRB1*1502 20 0.709 0.707 0.661 0.615 
DRB1*1503 2 0.608 0.707 0.753 0.745 
DRB1*1601 5 0.715 0.650 0.549 0.734 
DRB1*1602 3 0.666 0.975 0.932 0.900 
DRB3*0101 12 0.850 0.808 0.838 0.890 
DRB3*0202 10 0.613 0.596 0.646 0.492 
DRB3*0301 1 0.962 0.957 0.911 0.953 
DRB4*0101 17 0.717 0.725 0.581 0.586 
DRB4*0103 1 0.856 0.996 0.99 0.99 
DRB5*0101 55 0.735 0.773 0.729 0.722 
DRB5*0102 1 0.924 0.994 0.885 0.758 
      
Average  0.730 0.759 0.760 0.725 
  
Table S4 - MHC class II ligands with experimentally determined kinetic association 
rate constants (kon) obtained from the AntiJen database 
 
Epitope  Serotype  Species kon (M-1s-1) 
AERADLIAYLKAATAK  I-Ek MOUSE 47197.5 
AERADLIAYLKATAK I-Ek MOUSE 54000 
AERADLIAYLKQATA  I-Ek MOUSE 56333.3 
AERADLIAYLKQATAK I-Ek MOUSE 49110 
AERADLIAYLKQATK I-Ek MOUSE 42845 
AERADLIAYLKQATKK I-Ek MOUSE 44000 
ASQARPSQRHGSKYC I-Ak MOUSE 1166.7 
AYLKQATK I-Ek MOUSE 79000 
FAGIKKKANERADLIAYLKQATAK I-Ek MOUSE 51.5 
FAGLKKANERADLIAYLKQATK I-Ek MOUSE 42.5 
GAMNKALELFRKDIAAKYKELGYQG I-Ek MOUSE 5.9 
GKKVITAFNDGLK I-Ek MOUSE 58032.5 
IAGLGQGGK I-Ek MOUSE 70000 
IAPLPQPPK I-Ek MOUSE 83000 
IAYLKQA I-Ek MOUSE 140000 
IAYLKQAT I-Ek MOUSE 53667 
IAYLKQATK I-Ek MOUSE 216000 
ISQAVHAAHAEINEAGR I-Ad  MOUSE 0.9 
KPSVQLRMATPLLLR I-Ek MOUSE 400000 
KPSVQLRMATPLLMR I-Ek MOUSE 188233.3 
KPSVQMRMATELLMR I-Ek MOUSE 380000 
PKYVKQNTLKLATGM HLA-DR1  HUMAN 1300 
QMRMATPLLMR I-Ek MOUSE 270000 
VSRMRMATPLMQ HLA-DR1  HUMAN 100 
YLKQATK I-Ek MOUSE 143333.3 
YQAGFFLLTRILTIPQSLD HLA-DR4  HUMAN 17750 
    




Table S5 - Dataset of immunodominant CD4+ T cell epitopes 
 
N Pathogen Protein 
antigen 
ID Length Cluster Epitope Position Restriction Reference
s 




gi|94481520 566  YVKQNTLKL 324-332 DRB1*0101 [1-3] 
2 Influenza A virus 
(H1N1) 
M protein gi|238867319 252  FVFTLTVPS 62-70 DRB1*0401 [4] 
3 C. tetani Tetanus toxin 
(TT) 
gi|15022165 1310  YIKANSKFI 832-840 DRB1*0101 [5, 6] 
4 N. meningitidis Membrane 
protein Omp 






gi|710394 203  SLYNLRRGTAL 78-88 DRB1*0101 [8] 
6 Human 
herpesvirus 4 
BZLF1 protein gi|23893619 245  QHYREVAAAKSSE 198-210 DRB1*0101 [9] 
7 Cytomegalovirus 5 Envelope  
glycoprotein B 
gi|330505 718  DYSNTHSTRYV 217-227 DRB1*0701 [10, 11] 
8 Cytomegalovirus 5 Envelope 
Glycoprotein 
H 
gi|39842083 742  HELLVLVKKAQL 275-286 DRB1*1101 [10] 
9 Dengue virus 1 Polyprotein 
(NS3) 
gi|51850373 3392  VIGLYGNGV 1621-1629 DRB1*1501 [12, 13] 
10 Dengue virus 3 Polyprotein 
(NS3) 
gi|54401699 3390  WITDFVGKTVW 1824-1834 DRB1*1501 [12] 
11 Dengue virus 4 Polyprotein  
(capside) 
gi|12018170 3387  FRKEIGRML 83-91 DRB1*0101 [12, 14] 
12 Hepatitis C virus Polyprotein 
(NS3) 
gi|111283662 2939  VAYYRGLDV 1251-1259 DRB1*1501 [14] 
13 Hepatitis C virus Polyprotein 
(NS3) 
gi|111283662 2939  GRHLIFCHSKR  1388-1398 DRB1*1501 [14] 
14 Hepatitis C virus Polyprotein 
(NS3) 
gi|111283662 2939  VLVLNPSVA 1542-1550 DRB1*1201 [15, 16] 
15 Hepatitis C virus Polyprotein 
(NS3) 
gi|111283662 2939  YMNTPGLPV  1586-1594 DRB1*0701 [14, 16] 
16 Hepatitis C virus Polyprotein 
(NS3) 
gi|111283662 2939  LVAYQATVC 1694-1703 DRB1*1501 [14, 16] 
17 Hepatitis C virus Polyprotein 
(NS4) 
gi|111283662 2939  IVPDREVLYR 1775-1785 DRB1*0301 [14] 
18 Hepatitis C virus Polyprotein 
(NS4) 
gi|111283662 2939  LAGLSTLPGNP 1809-1817 DRB1*1104 [14, 16] 
19 Hepatitis C virus Polyprotein 
(NS4) 
gi|111283662 2939  FNILGGWVA 1879-1888 DRB1*0101 [14] 
20 Hepatitis C virus Polyprotein 
(NS4) 
gi|111283662 2939  LVNLLPAILS  1579-1587 DRB1*0101 [14] 
21 HIV (HXB2 strain) Gag  (p17) sp|P04591 500 ASRELERFAVNPGLL RELERFAVNGLL 39-49 DRB1*1302 [16, 17] 
22 HIV (HXB2 strain) Gag  (p17) sp|P04591 500 ASRELERFAVNPGLL ERFAVNPGLL 42-51 DRB3*0301 [17] 
23 HIV (HXB2 strain) Gag  (p24) sp|P04591 500 YVDRFYKTLRAEQASQEV RFYKTLRAEQ 300-308 DRB1*1101 [17, 18] 
24 HIV (HXB2 strain) Gag  (p24) sp|P04591 500 YVDRFYKTLRAEQASQEV VDRFYKTLR 298-306 DRB1*1301 [17, 18] 
25 HIV (HXB2 strain) Gag  (p24) sp|P04591 500 YVDRFYKTLRAEQASQEV FYKTLRAEQAS 301-311 DRB1*1501 [17, 18] 
26 HIV (HXB2 strain) Gag  (p24) sp|P04591 500 WIILGLNKIVRMYSPTSI NKIVRMYSPTSI 271-282 DRB1*1101 [17, 18] 
27 HIV (HXB2 strain) Gag  (p24) sp|P04591 500 WIILGLNKIVRMYSPTSI ILGLNKIVRMY 267-277 DRB1*1301 [17, 18] 
28 HIV (HXB2 strain) Gag  (p24) sp|P04591 500 WIILGLNKIVRMYSPTSI WIILGLNKIVRM 265-276 DRB1*0101 [17, 18] 
29 HIV (HXB2 strain) Gag  (p24) sp|P04591 500 WIILGLNKIVRMYSPTSI KIVRMYSPTS 272-281 DRB1*0101 [17-19] 
30 HIV (HXB2 strain) Gag  (p24) sp|P04591 500  EWDRVHPVHA 211-220 DRB1*0101 [19] 
1 HIV (HXB2 strain) Gag  (p24) sp|P04591 500  PIVQNIQGQMV 133-143 DRB1*0101 [19] 
32 HIV (HXB2 strain) Gag  (p24) sp|P04591 500  EVIPMFSALS 167-176 DRB1*0101 [19] 
33 M. tuberculosis Acr antigen gi|21629888 86 SEFAYGSFVRTVSLPVQAD FAYGSFVRT 66-74 DRB1*0101 [20] 
34 M. tuberculosis Acr antigen gi|21629888 86 SEFAYGSFVRTVSLPVQAD YGSFVRTVSL 68-77 DRB1*1501 [20] 
35 Y. enterocolitica Hsp60 gi|139472697 211  RVVINKDTTIII 148-159 DRB1*1302 [21, 22] 
36 P. falciparum CSP gi|160161 411 DIEKKIAKMEKASSVFNVVNS KKIAKMEKASS 381-391 DRB1*1101 [23, 24] 
37 P. falciparum CSP gi|160161 411 DIEKKIAKMEKASSVFNVVNS IAKMEKASSVFNV 383-394 DRB1*0401 [23, 24] 
38 P. falciparum CSP gi|160161 411 DIEKKIAKMEKASSVFNVVNS MEKASSVFNV 386-395 DRB1*0901 [23, 24] 
39 P. falciparum CSP gi|160161 411 EYLNKIQNSLSTEWSPCSVT KIQNSLSTEW 337-346 DRB1*0701 [25] 
40 P. falciparum CSP gi|160161 411 EYLNKIQNSLSTEWSPCSVT YLNKIQNSLSTEW 334-346 DRB1*0401 [26, 27] 
41 P. falciparum CSP gi|160161 411 EYLNKIQNSLSTEWSPCSVT LNKIQNSLSTEW 335-346 DRB1*0901 [27] 
42 S. pneumoniae Protein kinase 
(stpk) 
gi|165932151 637   FQISNYVGRKS 416-426 DRB1*1501 [28] 
 
Minimal immunogenic regions in epitope clusters are underlined. 
  
Table S6 - Benchmarking analysis of immunodominant CD4+ T cell epitope 
prediction for four pan-specific methods 
N 
 
Pathogen Protein antigen 
  
Predivac NetMHCIIPan TEPITOPEPan MultiRTA 
Ranking % Ranking % Ranking % Ranking % 
1 Influenza A virus (H3N2) Hemagglutinin (HA) 10 1.77 8 1.41 3 0.53 25 4.42 
2 Influenza A virus  (H1N1) M protein 3 1.19 1 0.40 1 0.40 1 0.40 
3 C. tetani Tetanus toxin (TT) 16 1.22 32 2.44 19 1.45 74 5.65 
4 N. meningitidis Membrane protein Omp 2 0.52 1 0.26 6 1.57 1 0.26 
5 Human herpesvirus 4 Nuclear antigen  
EBNA-1 
13 6.40 3 1.48 8 3.94 6 2.96 
6 Human herpesvirus 4 BZLF1 protein 2 0.82 2 0.82 3 1.22 1 0.41 
7 Cytomegalovirus 5 Envelope  
glycoprotein B 
6 0.84 38 5.29 22 3.06 6 0.84 
8 Cytomegalovirus 5 Envelope 
glycoprotein H 
3 0.40 8 1.08 5 0.67 55 7.41 
9 Dengue virus 1 Polyprotein (NS3) 20 0.59 45 1.33 89 2.62 6 0.18 
10 Dengue virus 3 Polyprotein (NS3) 8 0.24 618 18.23 325 9.59 394 11.62 
11 Dengue virus 4 Polyprotein  (capside) 11 0.32 16 0.47 14 0.41 8 0.24 
12 Hepatitis C virus Polyprotein (NS3) 10 0.34 109 3.71 2 0.07 712 24.23 
13 Hepatitis C virus Polyprotein (NS3) 612 20.82 3 0.10 2015 68.56 153 5.21 
14 Hepatitis C virus Polyprotein (NS3) 24 0.82 80 2.72 138 4.70 75 2.55 
15 Hepatitis C virus Polyprotein (NS3) 10 0.34 55 1.87 5 0.17 19 0.65 
16 Hepatitis C virus Polyprotein (NS3) 97 3.30 257 8.74 21 0.71 955 32.49 
17 Hepatitis C virus Polyprotein (NS4) 7 0.24 3 0.10 36 1.22 5 0.17 
18 Hepatitis C virus Polyprotein (NS4) 44 1.50 1005 34.20 79 2.69 125 4.25 
19 Hepatitis C virus Polyprotein (NS4) 7 0.24 111 3.78 8 0.27 15 0.51 
20 Hepatitis C virus Polyprotein (NS4) 36 1.22 24 0.82 7 0.24 9 0.31 
21 HIV (HXB2 strain) Gag  (p17) 61 12.20 190 38.00 466 93.20 362 72.40 
22 HIV (HXB2 strain) Gag  (p17) 27 5.40 42 8.40 463 92.60 172 34.40 
23 HIV (HXB2 strain) Gag  (p24) 12 2.40 4 0.80 11 2.20 89 17.80 
24 HIV (HXB2 strain) Gag  (p24) 1 0.20 59 11.80 42 8.40 96 19.20 
25 HIV (HXB2 strain) Gag  (p24) 14 2.80 41 8.20 78 15.60 39 7.80 
26 HIV (HXB2 strain) Gag  (p24) 8 1.60 8 1.60 2 0.40 5 1.00 
27 HIV (HXB2 strain) Gag  (p24) 5 1.00 4 0.80 6 1.20 1 0.20 
28 HIV (HXB2 strain) Gag  (p24) 26 5.20 12 2.40 1 0.20 10 2.00 
29 HIV (HXB2 strain) Gag  (p24) 4 0.80 1 0.20 3 0.60 3 0.60 
30 HIV (HXB2 strain) Gag  (p24) 2 0.40 53 10.60 16 3.20 50 10.00 
31 HIV (HXB2 strain) Gag  (p24) 3 0.60 15 3.00 5 1.00 16 3.20 
32 HIV (HXB2 strain) Gag  (p24) 3 0.60 7 1.40 11 2.20 8 1.60 
33 M. tuberculosis Acr antigen 15 17.44 4 4.65 5 5.81 8 9.30 
34 M. tuberculosis Acr antigen 1 1.16 6 6.98 3 3.49 6 6.98 
35 Y. enterocolitica Hsp60 6 2.84 1 0.47 6 2.84 6 2.84 
36 P. falciparum CSP 2 0.49 13 3.16 4 0.97 64 15.57 
37 P. falciparum CSP 9 2.19 18 4.38 31 7.54 30 7.30 
38 P. falciparum CSP 14 3.41 28 6.81 43 10.46 23 5.60 
39 P. falciparum CSP 16 3.89 36 8.76 8 1.95 11 2.68 
40 P. falciparum CSP 5 1.22 1 0.24 1 0.24 2 0.49 
41 P. falciparum CSP 27 6.57 15 3.65 15 3.65 22 5.35 
42 S. pneumoniae Protein kinase (stpk) 11 1.73 72 11.30 36 5.65 80 12.56 
        
Average 2.79   5.40   8.75   8.18 
Standard deviation  4.38   8.09   22.08   13.29 
 The ranking corresponds, in a list sorted by the scores, to the place occupied by the 
immunodominant epitope score among the scores of all same-length peptides in the source 
protein, while the percentage is calculated from the ratio of the score divided by the total 





Figure S1 - SDR positions. 
 
List of the SDR positions and criteria employed to select these positions in terms of 
polymorphism and calculated electrostatic effect on the binding groove. Columns 
correspond to the most conserved contacting positions identified in the MHC class II 
crystal structures analyzed. Rows are the peptide-binding positions (P1, P4, P6, P7 and P9). 
Cells in grey are highly polymorphic positions. In terms of electrostatic modelling, cells 
with letters A/a correspond to positions responsible for anchoring, while R/r corresponds to 
positions responsible for recognition. Uppercase corresponds to positions with a more 
significant effect [29, 30]. Dark grey cells are polymorphic positions and light grey cells are 
non-polymorphic positions. Although only polymorphic positions on the polymorphic β-
domain were considered for SDR selection, the non-polymorphic position 85 was 
considered because it determines the size of the deepest cavity and the main anchoring site 
of the binding groove.  
Figure S2 - Cross-validation. 
 
 
Predivac cross-validation on HLA class II alleles having more than 25 associated peptide 















Figure S3 - Predictive performance of four pan-specific methods in the identification 
of HLA class II DR1-restricted CD4+ T-cell epitopes of influenza virus. 
Predictive performance of Predivac, NetMHCIIPan, MultiRTA and TEPITOPEpan on 
DR1-restricted CD4+ T-cell epitopes from five infuenza virus (A/New 
Caledonia/20/1999(H1N1)) proteins: hemagglutinin (GenBank: AAP34324.1), 
neuraminidase (GenBank: ABW80984.1), nucleocapsid protein (GenBank: ACX46209.1), 
nonstructural protein 1 (GenBank: ACF41883.1) and the matrix protein 1 (GenBank: 
ACD37431.1).   
1 - Specificity
















Figure S4 – Predictive performance of four pan-specific methods in the identification 
















Predictive performance of Predivac, NetMHCIIPan, MultiRTA and TEPITOPEpan on 
DR4-restricted CD4+ T-cell epitopes from five infuenza virus (A/New 
Caledonia/20/1999(H1N1)) proteins: hemagglutinin (GenBank: AAP34324.1), 
neuraminidase (GenBank: ABW80984.1), nucleocapsid protein (GenBank: ACX46209.1), 
nonstructural protein 1 (GenBank: ACF41883.1) and the matrix protein 1 (GenBank: 
ACD37431.1).  
1 - Specificity






























Predictive performance of Predivac, NetMHCIIpan, TEPITOPEpan and MultiRTA in 
identifying immunodominant CD4+ T-cell epitopes. The fractional ROC curve 
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